To All Investors: DOC21 posted this info on 2/16/13 #897.
THIS is what excites ME:
If the Phase II/III clinical trial (Thailand or US, doesn't matter), comes about, the results will likely be dramatic, as Allostim worked best in the HER2+ breast cancer patients (the worst kind). If it comes to market, it will be competing in an essentially empty field, as nothing much works for late stage breast CA. It could therefore EASILY surpass $1 billion in sales in a short time (Avastin did over $7 billion in 1 year). Now, the market cap of a new, successful biotech often is 10-20 times gross sales. Assuming 10 times, then ITL could easly be worth 10 billion in a short time. IMUN could be as much as 25% of ITL if the deal works out. This would would make IMUN about $2.5 billion, and with about 200 million shares, would make a share price of $12.50!!! Now if Allostim is used for other cancers (which it will be), well, sky's the limit...
I sure hope this works out - we'll all be rich...
DOC21
His post stated IMUN could go to $12.50 with a 25% interest in
ITL. IMUN currently owns a 9% interest in ITL with this settlement. That works out to approx. $5.00 a share for IMUN with 200 million shares out. (assuming the drug works) This does not take into account when our GREAT CEO SETH SHAW is successful in making an acquisition of any other company in the Biotech space.
This is all great news for IMUN Shareholders.
Blackcat7717
